Warner Greene, MD, PhD

Headshot of Warner Greene
User Profile Photo

Warner Greene, MD, PhD

User Profile Name
Director, Gladstone Center for HIV Cure Research
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science. He also serves as Co-Director of the UCSF-Gladstone Center for AIDS Research, and has served as a Councilor and President of the Association of American Physicians. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as the Founding Director of the Gladstone Institute of Virology and Immunology in 1991. The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying HIV pathogenesis, latency, and transmission. He is the author of more than 380 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. In 2007, Dr. Greene expanded his work to include global health in sub-Saharan Africa in his service as president and executive chairman of the Accordia Global Health Foundation. Accordia established the Infectious Diseases Institute at Makerere University in Uganda, which has trained thousands of African health care workers, is caring for 30,000 HIV-infected patients, and has brought health care to nearly 500,000 people living in remote rural regions of Uganda. In 2016, Accordia merged with Africare.
CTSI Profile Bio

Displaying 101 - 125 of 386

  1. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, Schnolzer M, McBurney MW, Marmorstein R, Greene WC, Ott M. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. . 2008 Mar 13; 3(3):158-67.
  2. Chiu YL, Greene WC. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol. 2008; 26:317-53.
  3. Roan NR, Greene WC. A seminal finding for understanding HIV transmission. Cell. 2007 Dec 14; 131(6):1044-6.
  4. Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol. 2007 Nov; 37 Suppl 1:S94-102.
  5. Goffinet C, Michel N, Allespach I, Tervo HM, Hermann V, Kräusslich HG, Greene WC, Keppler OT. Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology. 2007 Jul 26; 4:53.
  6. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine. 2007 Jul; 39(1):63-74.
  7. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, Lewin SR, Gorry PR, Jaworowski A, Greene WC, Sonza S, Crowe SM. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol. 2007 May 15; 178(10):6581-9.
  8. Williams SA, Kwon H, Chen LF, Greene WC. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol. 2007 Jun; 81(11):6043-56.
  9. Soros VB, Greene WC. APOBEC3G and HIV-1: strike and counterstrike. Curr HIV/AIDS Rep. 2007 Feb; 4(1):3-9.
  10. Soros VB, Yonemoto W, Greene WC. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 2007 Feb; 3(2):e15.
  11. Cavrois M, Neidleman J, Kreisberg JF, Greene WC. In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog. 2007 Jan; 3(1):e4.
  12. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem. 2007 Feb 09; 282(6):3539-46.
  13. Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA. A plea for justice for jailed medical workers. Science. 2006 Nov 10; 314(5801):924-5.
  14. Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, Esnault C, Heidmann T, Greene WC. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A. 2006 Oct 17; 103(42):15588-93.
  15. O'Mahony A, Raber J, Montano M, Foehr E, Han V, Lu SM, Kwon H, LeFevour A, Chakraborty-Sett S, Greene WC. NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. Mol Cell Biol. 2006 Oct; 26(19):7283-98.
  16. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol. 2006 Nov; 80(21):10407-18.
  17. Soros VB, Greene WC. APOBEC3G and HIV-1: strike and counterstrike. Curr Infect Dis Rep. 2006 Jun; 8(4):317-23.
  18. Chiu YL, Greene WC. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol. 2006 Jun; 27(6):291-7.
  19. Kreisberg JF, Yonemoto W, Greene WC. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med. 2006 Apr 17; 203(4):865-70.
  20. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem. 2006 Jun 02; 281(22):15099-109.
  21. Cavrois M, Neidleman J, Kreisberg JF, Fenard D, Callebaut C, Greene WC. Human immunodeficiency virus fusion to dendritic cells declines as cells mature. J Virol. 2006 Feb; 80(4):1992-9.
  22. Chiu YL, Greene WC. APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J Biol Chem. 2006 Mar 31; 281(13):8309-12.
  23. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 2006 Jan 11; 25(1):139-49.
  24. Fenard D, Yonemoto W, de Noronha C, Cavrois M, Williams SA, Greene WC. Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol. 2005 Nov 01; 175(9):6050-7.
  25. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, Buckbinder L, Greene WC. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol. 2005 Sep; 25(18):7966-75.